JP2008530127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530127A5 JP2008530127A5 JP2007555303A JP2007555303A JP2008530127A5 JP 2008530127 A5 JP2008530127 A5 JP 2008530127A5 JP 2007555303 A JP2007555303 A JP 2007555303A JP 2007555303 A JP2007555303 A JP 2007555303A JP 2008530127 A5 JP2008530127 A5 JP 2008530127A5
- Authority
- JP
- Japan
- Prior art keywords
- rapamycin
- self
- emulsifying formulation
- use according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 39
- 239000000203 mixture Substances 0.000 claims 39
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 36
- 229960002930 sirolimus Drugs 0.000 claims 34
- 239000003814 drug Substances 0.000 claims 16
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 10
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 8
- 208000009745 Eye Disease Diseases 0.000 claims 8
- 208000002780 Macular Degeneration Diseases 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 8
- 239000002736 nonionic surfactant Substances 0.000 claims 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 6
- CBPNZQVSJQDFBE-RERLVDEVSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)C(C)=CC=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-RERLVDEVSA-N 0.000 claims 6
- -1 analogs Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 229960000235 temsirolimus Drugs 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 206010013774 Dry eye Diseases 0.000 claims 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 4
- KASDHRXLYQOAKZ-XDSKOBMDSA-N Pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 claims 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 4
- 229960001967 Tacrolimus Drugs 0.000 claims 4
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 4
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 4
- 229950009819 Zotarolimus Drugs 0.000 claims 4
- 201000011190 diabetic macular edema Diseases 0.000 claims 4
- 229960005167 everolimus Drugs 0.000 claims 4
- 229960005330 pimecrolimus Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrugs Drugs 0.000 claims 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 3
- CGTADGCBEXYWNE-BJFMSCRISA-N Zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](C(C)=CC=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-BJFMSCRISA-N 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 3
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical group CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 claims 2
- 210000003161 Choroid Anatomy 0.000 claims 2
- 102000001493 Cyclophilins Human genes 0.000 claims 2
- 108010068682 Cyclophilins Proteins 0.000 claims 2
- BUROJSBIWGDYCN-GAUTUEMISA-N Deforolimus Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 2
- SRIDGLJAFSFWOP-XOPIUEIMSA-N Demethoxyrapamycin Chemical compound C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)/C(C)=C/C=C/C=C/C(C)CC(C)C(=O)CC(O)/C(C)=C/C(C)C(=O)C1 SRIDGLJAFSFWOP-XOPIUEIMSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 125000005313 fatty acid group Chemical group 0.000 claims 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 2
- 230000002207 retinal Effects 0.000 claims 2
- 235000020945 retinal Nutrition 0.000 claims 2
- 239000011604 retinal Substances 0.000 claims 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 2
- 210000000795 Conjunctiva Anatomy 0.000 claims 1
- 210000003786 Sclera Anatomy 0.000 claims 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N Zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
Claims (45)
- 被験体における眼の疾患を処置するための医薬の調製のための、ラパマイシンを含む自己乳化処方物の使用であって、ラパマイシンは、0.1w/w%〜5w/w%ラパマイシンの濃度で該医薬中に存在する、使用。
- 前記自己乳化処方物は、ウサギの眼の硝子体に注射されると、ウサギの眼への自己乳化処方物の投与後少なくとも7日の期間にわたり、少なくとも約0.001ng/mlのラパマイシン濃度に等しい治療薬の平均濃度を該ウサギの眼の網膜脈絡膜にもたらすのに十分な量の治療薬を送達する、請求項1に記載の使用。
- 前記自己乳化処方物に、さらに溶媒および非イオン性界面活性剤が含まれている、請求項1または2のいずれか1項に記載の使用。
- 前記非イオン性界面活性剤が約10より大きいHLB値を有している、請求項3に記載の使用。
- 前記眼の疾患が、脈絡膜血管新生、萎縮型加齢黄斑変性症、滲出型加齢黄斑変性症、糖尿病性黄斑浮腫、糖尿病性網膜症、およびドライアイからなる群より選択される、請求項1〜4のいずれか1項に記載の使用。
- 被験体において眼の疾患を処置するための医薬の調製のための、ラパマイシンの哺乳動物標的(mTOR)阻害剤および/またはイムノフィリン結合化合物である治療薬剤を含む自己乳化処方物の使用。
- 前記自己乳化処方物は、ウサギの眼の硝子体に注射されると、ウサギの眼への自己乳化処方物の投与後少なくとも7日の期間にわたり、少なくとも約0.001ng/mlのラパマイシン濃度に等しい治療薬の平均濃度を該ウサギの眼の網膜脈絡膜にもたらすのに十分な量の治療薬を送達する、請求項6に記載の使用。
- 前記治療薬が、前記mTOR阻害剤である、請求項6または7のいずれか1項に記載の使用。
- 前記mTOR阻害剤が、ラパマイシン、その薬学的に受容可能なプロドラッグ、アナログ、塩、およびエステルからなる群より選択される、請求項8に記載の使用。
- 前記治療薬が、ラパマイシン、SDZ−RAD、タクロリムス、エベロリムス、ピメクロリムス、CCI−779、AP23841、ABT−578、サイクロフィリン、FK506結合タンパク質(FKBP)、TAFA−93、RAD−001、テムシロリムス、AP23573、7−エピ−ラパマイシン、7−チオメチル−ラパマイシン、7−エピ−トリメトキシフェニル−ラパマイシン、7−エピ−チオメチル−ラパマイシン、7−デメトキシ−ラパマイシン、32−デメトキシ−ラパマイシン、2−デスメチル−ラパマイシン、ラパマイシンのモノエステル誘導体、ラパマイシンのジエステル誘導体、ラパマイシンの27−オキシム;ラパマイシンの42−オキソアナログ;二環式ラパマイシン;ラパマイシンダイマー;ラパマイシンのシリルエーテル;ラパマイシンアリールスルホネート、ラパマイシンスルファミン酸塩、31位および42位でのモノエステル、31位および42位でのジエステル、30−デメトキシラパマイシン、およびそれらの薬学的に受容可能なプロドラッグ、アナログ、塩およびエステルからなる群から選択される、請求項6に記載の使用。
- 前記治療薬が、ラパマイシン、SDZ−RAD、タクロリムス、エベロリムス、ピメクロリムス、CCI−779、AP23841、ABT−578、およびそれらの薬学的に受容可能な塩およびエステルからなる群から選択される、請求項6に記載の使用。
- 前記治療薬が、ラパマイシンである、請求項10または11のいずれか1項に記載の使用。
- 前記眼の疾患が、脈絡膜血管新生、萎縮型加齢黄斑変性症、滲出型加齢黄斑変性症、糖尿病性黄斑浮腫、糖尿病性網膜症、およびドライアイからなる群より選択される、請求項6〜12のいずれか1項に記載の使用。
- 前記眼の疾患が、萎縮型加齢黄斑変性症である、請求項13に記載の使用。
- 前記眼の疾患が、滲出型加齢黄斑変性症である、請求項13に記載の使用。
- 前記眼の疾患が、糖尿病性黄斑浮腫である、請求項13に記載の使用。
- 前記眼の疾患が、糖尿病性網膜症である、請求項13に記載の使用。
- 前記眼の疾患が、ドライアイである、請求項13に記載の使用。
- 前記自己乳化処方物が前記被験体の眼の硝子体中に入れられる、請求項6〜18のいずれか1項に記載の使用。
- 前記自己乳化処方物が前記被験体の眼の強膜と結膜との間に入れられる、請求項6〜18のいずれか1項に記載の使用。
- 前記自己乳化処方物にさらに溶媒および界面活性剤が含まれている、請求項6〜20のいずれか1項に記載の使用。
- 前記界面活性剤が非イオン性界面活性剤である、請求項21に記載の使用。
- 前記非イオン性界面活性剤が約10より大きいHLB値を有している、請求項22に記載の使用。
- 前記非イオン性界面活性剤がCremophor ELである、請求項23に記載の使用。
- 前記溶媒が脂肪酸である、請求項21に記載の使用。
- 前記溶媒が、オレイン酸、Imwitor742、Softigen767、またはCapmuls PG8からなる群より選択される、請求項21に記載の使用。
- ラパマイシンの哺乳動物標的(mTOR)阻害剤および/またはイムノフィリン結合化合物である治療薬と、溶媒と、界面活性剤とを含む自己乳化処方物であって、該自己乳化処方物は被験体の眼の水性媒体中に入れられるように処方されている、自己乳化処方物。
- 前記治療薬が、ラパマイシンの哺乳動物標的(mTOR)阻害剤である、請求項27に記載の自己乳化処方物。
- 前記mTOR阻害剤が、ラパマイシン、ならびにその薬学的に受容可能なプロドラッグ、アナログ、塩およびエステルからなる群より選択される、請求項28に記載の自己乳化処方物。
- 前記治療薬が、ラパマイシン、SDZ−RAD、タクロリムス、エベロリムス、ピメクロリムス、CCI−779、AP23841、ABT−578、サイクロフィリン、FK506結合タンパク質(FKBP)、TAFA−93、RAD−001、テムシロリムス、AP23573、7−エピ−ラパマイシン、7−チオメチル−ラパマイシン、7−エピ−トリメトキシフェニル−ラパマイシン、7−エピ−チオメチル−ラパマイシン、7−デメトキシ−ラパマイシン、32−デメトキシ−ラパマイシン、2−デスメチル−ラパマイシン、ラパマイシンのモノエステル誘導体、ラパマイシンのジエステル誘導体、ラパマイシンの27−オキシム;ラパマイシンの42−オキソアナログ;二環式ラパマイシン;ラパマイシンダイマー;ラパマイシンのシリルエーテル;ラパマイシンアリールスルホネート、ラパマイシンスルファミン酸塩、31位および42位でのモノエステル、31位および42位でのジエステル、30−デメトキシラパマイシン、およびそれらの薬学的に受容可能なプロドラッグ、アナログ、塩およびエステルからなる群から選択される、請求項27に記載の自己乳化処方物。
- 前記治療薬が、ラパマイシン、SDZ−RAD、タクロリムス、エベロリムス、ピメクロリムス、CCI−779、AP23841、ABT−578、およびそれらの薬学的に受容可能な塩およびエステルからなる群から選択される、請求項27に記載の自己乳化処方物。
- 前記自己乳化処方物が、ラパマイシンである、請求項30または31のいずれか1項に記載の自己乳化処方物。
- 前記自己乳化処方物は、被験体に投与されると、該被験体の脈絡膜新生血管形成を処置するために有効な量のラパマイシンを送達する、請求項27〜32のいずれか1項に記載の自己乳化処方物。
- 前記自己乳化処方物は、被験体に投与されると、該被験体の滲出型加齢性黄斑変性を処置するために有効な量のラパマイシンを送達する、請求項27〜32のいずれか1項に記載の自己乳化処方物。
- 前記自己乳化処方物は、被験体に投与されると、該被験体の滲出型加齢性黄斑変性を処置するために有効な量のラパマイシンを送達する、請求項27〜32のいずれか1項に記載の自己乳化処方物。
- 前記自己乳化処方物は、被験体に投与されると、該被験体の糖尿病性黄斑浮腫を処置するために有効な量のラパマイシンを送達する、請求項27〜32のいずれか1項に記載の自己乳化処方物。
- 前記自己乳化処方物は、被験体に投与されると、該被験体の糖尿病性網膜症を処置するために有効な量のラパマイシンを送達する、請求項27〜32のいずれか1項に記載の自己乳化処方物。
- 前記自己乳化処方物は、被験体に投与されると、該被験体のドライアイを処置するために有効な量のラパマイシンを送達する、請求項27〜32のいずれか1項に記載の自己乳化処方物。
- 前記界面活性剤が非イオン性である、請求項27〜38のいずれか1項に記載の自己乳化処方物。
- 前記界面活性剤が約10より大きいHLB値を有している、請求項39に記載の自己乳化処方物。
- 前記非イオン性界面活性剤がCremophor ELである、請求項40に記載の自己乳化処方物。
- 前記溶媒が脂肪酸である、請求項27〜41のいずれか1項に記載の自己乳化処方物。
- 前記溶媒が、オレイン酸、Imwitor742、Softigen767、またはCapmuls PG8からなる群より選択される、請求項27〜42のいずれか1項に記載の自己乳化処方物。
- 前記自己乳化処方物に、0.1%w/wから5%w/wの間のラパマイシン;約40%w/wから約50%w/wの間の溶媒;および40%w/wから50%w/wの間の非イオン性界面活性剤が含まれている、請求項27に記載の自己乳化処方物。
- さらにエタノールが含まれている、請求項27〜44のいずれか1項に記載の自己乳化処方物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65179005P | 2005-02-09 | 2005-02-09 | |
US66430605P | 2005-03-21 | 2005-03-21 | |
US66404005P | 2005-03-21 | 2005-03-21 | |
PCT/US2006/004955 WO2006086744A1 (en) | 2005-02-09 | 2006-02-09 | Formulations for ocular treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008530127A JP2008530127A (ja) | 2008-08-07 |
JP2008530127A5 true JP2008530127A5 (ja) | 2009-03-12 |
Family
ID=36793384
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007555305A Active JP4974903B2 (ja) | 2005-02-09 | 2006-02-09 | 疾患または状態を処置するための液体処方物 |
JP2007555303A Pending JP2008530127A (ja) | 2005-02-09 | 2006-02-09 | 眼の処置のための処方物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007555305A Active JP4974903B2 (ja) | 2005-02-09 | 2006-02-09 | 疾患または状態を処置するための液体処方物 |
Country Status (17)
Country | Link |
---|---|
US (11) | US20060182771A1 (ja) |
EP (3) | EP3025713A1 (ja) |
JP (2) | JP4974903B2 (ja) |
KR (3) | KR20070104931A (ja) |
CN (1) | CN104147005B (ja) |
AU (2) | AU2006213588B2 (ja) |
BR (2) | BRPI0608152A2 (ja) |
CA (2) | CA2597596C (ja) |
CY (1) | CY1117357T1 (ja) |
DK (1) | DK1848431T3 (ja) |
ES (1) | ES2564194T3 (ja) |
GB (1) | GB2438544A (ja) |
HK (3) | HK1110215A1 (ja) |
HU (1) | HUE027352T2 (ja) |
PL (1) | PL1848431T3 (ja) |
SI (1) | SI1848431T1 (ja) |
WO (2) | WO2006086750A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7051721B2 (ja) | 2016-06-30 | 2022-04-11 | デュレクト コーポレーション | デポー製剤 |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
AU2004274026A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US8288362B2 (en) * | 2004-05-07 | 2012-10-16 | S.K. Pharmaceuticals, Inc. | Stabilized glycosaminoglycan preparations and related methods |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
DK1848431T3 (en) * | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
US20060257450A1 (en) * | 2005-03-21 | 2006-11-16 | Sreenivasu Mudumba | Drug delivery systems for treatment of diseases or conditions |
US20060222596A1 (en) | 2005-04-01 | 2006-10-05 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
AU2007212271B2 (en) | 2006-02-09 | 2012-11-01 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
AU2013200089B2 (en) * | 2006-02-09 | 2016-03-03 | Santen Pharmaceutical Co., Ltd | Stable formulations, and methods of their preparation and use |
AU2007230964B2 (en) | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
US7872068B2 (en) | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
WO2008021088A2 (en) * | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
RU2010104916A (ru) * | 2006-08-16 | 2011-08-20 | Михаил В. Благосклонный (US) | Способ профилактики и лечения возрастных заболеваний |
US9205080B2 (en) | 2006-11-16 | 2015-12-08 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors |
US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
WO2008120249A1 (en) * | 2007-03-30 | 2008-10-09 | Sifi S.P.A. | Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
AU2014201863B2 (en) * | 2007-04-30 | 2017-02-02 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
AU2007356856A1 (en) * | 2007-07-20 | 2009-01-29 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKI) compounds to the eye |
WO2009018333A2 (en) * | 2007-07-30 | 2009-02-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
WO2009023877A2 (en) * | 2007-08-16 | 2009-02-19 | Macusight, Inc. | Formulations for treatment of ocular diseases or conditions |
WO2009048929A1 (en) | 2007-10-08 | 2009-04-16 | Lux Biosciences, Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
CA2702761A1 (en) * | 2007-11-01 | 2009-05-07 | Bausch & Lomb Incorporated | Non-aqueous water-miscible materials as vehicles for drug delivery |
WO2009067217A1 (en) * | 2007-11-20 | 2009-05-28 | Ceramoptec Industries, Inc. | Pdt assisted scar prevention and vision correction |
US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
EP2286224A4 (en) * | 2008-05-05 | 2012-04-25 | Univ Winthrop Hospital | METHOD FOR IMPROVING THE CARDIOVASCULAR RISK PROFILE OF COX-INHIBITORS |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
PT2365802T (pt) | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
DE102008059201A1 (de) * | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ präzipitierende Arzneistofflösungen |
WO2010065024A1 (en) * | 2008-12-05 | 2010-06-10 | Kador Peter F | Topical treatment of cataracts in dogs |
JP5890182B2 (ja) | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | ヒドロゲルプラグによる薬物送達 |
US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
ES2685947T3 (es) | 2009-04-10 | 2018-10-15 | Haiyan Qi | Agentes antienvejecimiento |
JP2010260857A (ja) * | 2009-04-10 | 2010-11-18 | Santen Pharmaceut Co Ltd | シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤 |
CA2760932A1 (en) * | 2009-05-04 | 2010-11-11 | Thierry Nivaggioli | Mtor pathway inhibitors for treating ocular disorders |
WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US9480645B2 (en) * | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
AU2014250656B2 (en) * | 2009-06-02 | 2016-05-05 | Johnson & Johnson Surgical Vision, Inc. | Omega-3 oil containing ophthalmic emulsions |
US20100303915A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Therapeutic opthalmic emulsions |
US20100305046A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
EP2440185B1 (en) | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
TWI492769B (zh) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
EP2308468A1 (en) * | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
US9717703B2 (en) | 2009-10-16 | 2017-08-01 | Glaxosmithkline Llc | Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
CN102753150A (zh) | 2010-01-12 | 2012-10-24 | 诺沃—诺迪斯克有限公司 | 用于口服给予胰岛素肽的药物组合物 |
US8961501B2 (en) * | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
EP2641597A4 (en) * | 2010-11-19 | 2014-04-30 | Nippon Suisan Kaisha Ltd | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CORNEAL EPITHELIUM DISORDERS AND / OR CONNECTIVE EPITHELIUM DISORDERS |
KR101214362B1 (ko) | 2011-02-15 | 2012-12-21 | 한림대학교 산학협력단 | Fk506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물 |
CN102653779B (zh) * | 2011-03-04 | 2014-02-19 | 北京科润三联生物技术有限责任公司 | 一种新型重组抗菌多肽药物的制备方法 |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
US8716363B2 (en) * | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
CN103127052A (zh) * | 2011-12-05 | 2013-06-05 | 维瑞斯特姆有限公司 | 治疗组合物和相关使用方法 |
AU2012347926B2 (en) | 2011-12-05 | 2018-03-15 | Incept, Llc | Medical organogel processes and compositions |
WO2013109354A2 (en) * | 2011-12-07 | 2013-07-25 | Texas Southern University | Etravirine formulations and uses thereof |
US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
WO2014169708A1 (en) * | 2013-04-18 | 2014-10-23 | The Hong Kong University Of Science And Technology | Biocompatible in situ hydrogel |
MX2016003566A (es) | 2013-09-20 | 2016-06-02 | Santen Pharmaceutical Co Ltd | Composicion que contiene polietilen glicol. |
DK3089737T3 (da) * | 2013-12-31 | 2021-12-13 | Rapamycin Holdings Llc | Orale rapamycin-nanopartikelpræparater og anvendelse. |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
EP2946788A1 (en) | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
CA2963871A1 (en) * | 2014-10-08 | 2016-04-14 | Maamar ACHACHA | Altrenogest formulation and uses thereof for estrus synchronisation in animals |
US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
KR20170120161A (ko) | 2015-03-05 | 2017-10-30 | 알러간, 인코포레이티드 | 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds) |
EP3272362B1 (en) * | 2015-03-18 | 2023-12-13 | Santen Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
AU2016263176A1 (en) | 2015-05-20 | 2017-12-07 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
CN108024914A (zh) | 2015-09-17 | 2018-05-11 | Jrx生物技术有限公司 | 改善皮肤的水合作用或润湿作用的方法 |
EP3351245A4 (en) * | 2015-09-18 | 2019-05-22 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF |
SG11201802091RA (en) * | 2015-09-18 | 2018-04-27 | Santen Pharmaceutical Co Ltd | Fungal keratitis prophylactic or therapeutic agent |
WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
JP6905527B2 (ja) | 2015-12-17 | 2021-07-21 | ピーティーシー セラピューティクス, インコーポレイテッド | 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ1,4−ベンゾキノン誘導体 |
EP3423041A4 (en) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | PHARMACEUTICAL COMPOSITIONS |
WO2017184881A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
KR102373289B1 (ko) * | 2016-05-25 | 2022-03-10 | 산텐 세이야꾸 가부시키가이샤 | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 |
ES2902006T3 (es) | 2016-06-27 | 2022-03-24 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos médicos |
US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
BR112019010470A2 (pt) | 2016-11-23 | 2019-09-10 | Novartis Ag | métodos de realce de resposta imune com everolimo, dactolisib ou ambos |
EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
IL267869B2 (en) * | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
WO2018151143A1 (ja) * | 2017-02-17 | 2018-08-23 | 参天製薬株式会社 | 製剤密封容器およびその利用 |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
EP3624863B1 (en) | 2017-05-15 | 2021-04-14 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
JP7278969B2 (ja) * | 2017-05-30 | 2023-05-22 | エキシモア・リミテッド | ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法 |
CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
MX2019015475A (es) | 2017-06-30 | 2020-02-19 | Univ California | Composiciones y metodos para modular el crecimiento del cabello. |
JP7150281B2 (ja) * | 2017-07-20 | 2022-10-11 | 国立研究開発法人理化学研究所 | 連続的な上皮を含む網膜組織の成熟化方法 |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
WO2020081723A1 (en) | 2018-10-16 | 2020-04-23 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
WO2020101675A1 (en) | 2018-11-14 | 2020-05-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
EP3886852B1 (en) * | 2018-12-03 | 2024-01-31 | Smilebiotek Zhuhai Limited | Octyl gallate and esters thereof of for use in the treatment and prevention of age-related macular degeneration caused by bacillus megaterium |
US20220079899A1 (en) * | 2019-01-14 | 2022-03-17 | The Regents Of The University Of California | Compositions and methods for treating ocular conditions |
JP2022528966A (ja) | 2019-04-08 | 2022-06-16 | バード・ペリフェラル・バスキュラー・インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
KR20220062617A (ko) * | 2019-09-13 | 2022-05-17 | 알데이라 테라퓨틱스, 아이엔씨. | 메토트렉세이트의 안과용 제형 |
CA3164165A1 (en) * | 2020-01-10 | 2021-07-15 | Robert Bruce Register | Topical compositions containing rofecoxib and methods of making and using the same |
WO2022271702A1 (en) * | 2021-06-21 | 2022-12-29 | Palvella Therapeutics, Inc. | Methods and compositions for treating gorlin syndrome |
WO2023225373A1 (en) * | 2022-05-20 | 2023-11-23 | Dermbiont, Inc. | Compositions and formulations for use of a pk inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders |
US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (270)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2007538A (en) * | 1934-04-10 | 1935-07-09 | Louis Stern Company | Bracelet end hook |
US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
US3828777A (en) | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US3914402A (en) | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
US3926188A (en) | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
FR2382240A1 (fr) | 1977-03-03 | 1978-09-29 | Mouls Pierre | Dispositif permettant d'instiller des liquides medicamenteux dans l'oeil |
US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
AU543727B2 (en) | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
IT1141715B (it) | 1980-06-06 | 1986-10-08 | Sadepan Chimica Spa | Collante a base di resina urea-formaldeide additivato con ligninsolfonato di calcio e/o ammonio,resina urea formaldeide modificata con ligninsolfonato di calcio e/o ammonio e metodo di produzione degli stessi,per la preparazione di pannelli agglomerati di legno |
US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
EP0391909B1 (en) | 1987-09-03 | 1994-08-17 | The University Of Georgia Research Foundation, Inc. | Ocular cyclosporin composition |
US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
EP0356399A3 (en) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them |
US4946450A (en) | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5883082A (en) * | 1990-08-14 | 1999-03-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for preventing and treating allograft rejection |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
DE4022553A1 (de) | 1990-07-16 | 1992-01-23 | Hund Helmut Gmbh | Vorrichtung zur hochreproduzierbaren applikation definierter volumina von loesungen und suspensionen diagnostisch oder therapeutisch wirksamer substanzen auf der cornea-oberflaeche |
US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5290892A (en) * | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
IE65341B1 (en) | 1990-11-08 | 1995-10-18 | Fujisawa Pharmaceutical Co | Suspensions containing tricyclic compounds |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
KR100237715B1 (ko) * | 1991-04-26 | 2000-02-01 | 후지야마 아키라 | 안과질환에 대한 마크로라이드 화합물의 용도 |
US5565560A (en) | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
US5120727A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
US5120725A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
US5457111A (en) | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
WO1993019763A1 (en) * | 1992-03-30 | 1993-10-14 | American Home Products Corporation | Rapamycin formulation for iv injection |
US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
FR2690846B1 (fr) * | 1992-05-05 | 1995-07-07 | Aiache Jean Marc | Forme galenique pour administration oculaire et procede de preparation. |
US5858340A (en) * | 1992-05-22 | 1999-01-12 | The Procter & Gamble Company | Cosmetic compositions |
WO1994005257A1 (en) | 1992-09-08 | 1994-03-17 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
DE69326015T2 (de) * | 1992-11-18 | 2000-02-03 | Fujisawa Pharmaceutical Co | Pharmazeutische zubereitung mit verlängerter wirkung |
CA2156065A1 (en) | 1993-03-17 | 1994-09-29 | Rolf Wagner | Macrocyclic amide and urea immunomodulators |
GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
ATE154757T1 (de) * | 1993-07-19 | 1997-07-15 | Angiotech Pharm Inc | Anti-angiogene mittel und verfahren zu deren verwendung |
WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
IL111003A0 (en) | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5516770A (en) * | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
NZ277498A (en) * | 1993-12-17 | 1998-03-25 | Novartis Ag | Rapamycin derivatives |
US5788687A (en) | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
US5773021A (en) * | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
EP0754046A1 (en) | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US5621108A (en) * | 1994-12-05 | 1997-04-15 | Trustees Of The University Of Pennsylvania | Processes and intermediates for preparing macrocycles |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
WO1996036377A1 (en) | 1995-05-14 | 1996-11-21 | Optonol Ltd. | Intraocular implant, delivery device, and method of implantation |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
JPH0930966A (ja) | 1995-07-24 | 1997-02-04 | Gakuzo Tamura | 眼科用新規製剤 |
DE69630798T2 (de) | 1995-09-19 | 2004-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Aerosolzusammensetzungen |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
JPH11514648A (ja) | 1995-10-31 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 免疫抑制活性をもつトリテルペン誘導体 |
GB9601120D0 (en) * | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
ES2243978T3 (es) | 1996-02-13 | 2005-12-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4. |
US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
US5743274A (en) * | 1996-03-18 | 1998-04-28 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular members |
US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
JP3309175B2 (ja) | 1996-03-25 | 2002-07-29 | 参天製薬株式会社 | タンパク性薬物含有強膜プラグ |
JPH09315954A (ja) | 1996-05-30 | 1997-12-09 | Kita:Kk | 眼科手術後の眼組織混濁防止剤。 |
GB9710962D0 (en) * | 1997-05-28 | 1997-07-23 | Univ Cambridge Tech | Polyketides and their synthesis |
RU2123314C1 (ru) | 1996-06-27 | 1998-12-20 | Павлова Татьяна Вячеславовна | Способ постановки ирригационной системы в теноново пространство |
AU730781B2 (en) | 1996-07-30 | 2001-03-15 | Novartis Ag | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxiethyl)-rapamycin |
US6007510A (en) | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
US6142969A (en) | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
AUPO427196A0 (en) | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
JPH10218787A (ja) | 1997-02-06 | 1998-08-18 | Akio Okamoto | 神経栄養因子による眼科用組成物 |
TW450810B (en) * | 1997-02-20 | 2001-08-21 | Fujisawa Pharmaceutical Co | Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
EP1003569B1 (en) * | 1997-08-11 | 2004-10-20 | Allergan, Inc. | Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
US20060198867A1 (en) | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
US20030190286A1 (en) | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
TR200001117T2 (tr) | 1997-10-22 | 2000-09-21 | Ponikau Jens | Mukozal dokudaki enflomasyonu önlemek ve tedavi etmek için maddeler ve yöntemler. |
ZA989885B (en) | 1997-10-31 | 1999-05-05 | Abbott Lab | Use of macrolides for the treatment of cancer and macular degeneration |
CZ287497B6 (cs) | 1997-12-30 | 2000-12-13 | Galena, A. S. | Topické oční přípravky s imunosupresivními látkami |
AU2337599A (en) | 1998-01-23 | 1999-08-09 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
DE19810655A1 (de) | 1998-03-12 | 1999-09-16 | Univ Eberhard Karls | Arzneimittel mit einem Gehalt an Ciclosporin |
JP2002506028A (ja) | 1998-03-13 | 2002-02-26 | ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン | 糖尿病性網膜症または眼炎症の処置におけるゲニステインのようなタンパク質チロシンインヒビターの使用 |
US6482802B1 (en) | 1998-05-11 | 2002-11-19 | Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
AU748867B2 (en) | 1998-07-24 | 2002-06-13 | Jagotec Ag | Medicinal aerosol formulations |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
US6384056B1 (en) | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
DK1143917T3 (da) | 1998-11-17 | 2004-06-01 | Ortho Mcneil Pharm Inc | Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom |
GB9826882D0 (en) | 1998-12-07 | 1999-01-27 | Novartis Ag | Organic compounds |
WO2000033862A1 (en) * | 1998-12-11 | 2000-06-15 | Pharmasolutions, Inc. | Self-emulsifying compositions for drugs poorly soluble in water |
US6399655B1 (en) | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
EA005815B1 (ru) * | 1998-12-23 | 2005-06-30 | Джи.Ди.Сирл Ллс | Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний |
US6864232B1 (en) * | 1998-12-24 | 2005-03-08 | Sucampo Ag | Agent for treating visual cell function disorder |
EP1140134A1 (en) | 1998-12-24 | 2001-10-10 | R-Tech Ueno, Ltd. | Agent for treating visual cell function disorder |
EP1154691A4 (en) | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | TARGETED ADMINISTRATION OF REGULATED RELEASE MEDICINE TO RETINA AND CHOROID THROUGH SCLEROTIC |
US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US6254860B1 (en) * | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
CA2372448A1 (en) | 1999-04-30 | 2000-11-09 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US7063857B1 (en) * | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
AU5273200A (en) * | 1999-05-24 | 2000-12-12 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
JP2001064198A (ja) | 1999-08-24 | 2001-03-13 | Teika Seiyaku Kk | 角膜疾患治療剤 |
BR0015053A (pt) | 1999-10-18 | 2002-07-02 | Fujisawa Pharmaceutical Co | Método para produzir uma preparação de lipossoma e preparação de lipossoma |
BR0014929B1 (pt) | 1999-10-21 | 2009-01-13 | dispositivo para distribuiÇço de medicamento oftÁlmico. | |
US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
JP2003511204A (ja) | 1999-10-21 | 2003-03-25 | アルコン,インコーポレイティド | テノン下薬剤送出 |
NZ518483A (en) * | 1999-10-22 | 2004-03-26 | Biogen Inc | Use of CD40:CD154 binding interruptor to treat immunological complications of the eye |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
WO2001030337A2 (en) * | 1999-10-22 | 2001-05-03 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
ES2283344T3 (es) | 1999-10-29 | 2007-11-01 | Kosan Biosciences, Inc. | Analogos de la rapamicina. |
RU2149615C1 (ru) | 1999-11-10 | 2000-05-27 | Нестеров Аркадий Павлович | Способ введения лекарственных препаратов при заболеваниях заднего отрезка глаза |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
DZ3227A1 (fr) | 1999-12-23 | 2001-07-05 | Pfizer Prod Inc | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees |
GB0003932D0 (en) | 2000-02-18 | 2000-04-12 | Novartis Ag | Pharmaceutical compositions |
US6489335B2 (en) | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
ES2206363T3 (es) | 2000-04-07 | 2004-05-16 | Laboratoire Medidom S.A. | Formulaciones oftalmicas a base de ciclosporina, de acido hialuronico y de polisorbato. |
US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
CN1127955C (zh) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
CN1204919C (zh) | 2000-08-30 | 2005-06-08 | 中国科学院化学研究所 | 长效环孢素眼内释药体系 |
ATE547080T1 (de) * | 2000-08-30 | 2012-03-15 | Univ Johns Hopkins | Vorrichtungen zur intraokularen arzneimittelabgabe |
WO2002028387A1 (en) | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
US20050084514A1 (en) * | 2000-11-06 | 2005-04-21 | Afmedica, Inc. | Combination drug therapy for reducing scar tissue formation |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
WO2002043785A2 (en) * | 2000-11-29 | 2002-06-06 | Oculex Pharmaceuticals, Inc. | Intraocular implants for preventing transplant rejection in the eye |
CA2433032C (en) | 2001-01-03 | 2008-11-25 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with coated drug cores |
EP2314293B1 (en) | 2001-01-16 | 2017-01-04 | Vascular Therapies, LLC | Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases |
US7181287B2 (en) * | 2001-02-13 | 2007-02-20 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
SK288546B6 (sk) | 2001-02-19 | 2018-03-05 | Novartis Ag | 40-O-(2-hydroxyetyl)rapamycín v kombinácii s exemestánom alebo letrozolom na použitie pri liečení nádoru prsníka |
US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
AR033151A1 (es) | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
JP2004536631A (ja) * | 2001-05-03 | 2004-12-09 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 移植可能な薬物送達デバイスおよびその使用 |
JP2002332225A (ja) | 2001-05-09 | 2002-11-22 | Lion Corp | 眼科用組成物 |
EP1404297B1 (en) | 2001-06-12 | 2011-04-27 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US7034037B2 (en) * | 2001-06-29 | 2006-04-25 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
US6787179B2 (en) | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
NZ530845A (en) * | 2001-07-06 | 2006-03-31 | Sucampo Ag | Composition for topical administration |
US6599891B2 (en) | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
AR035293A1 (es) | 2001-08-23 | 2004-05-05 | Novartis Ag | Composicion oftalmica. |
US6812220B2 (en) | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
US6656460B2 (en) | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
JP2005511576A (ja) * | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
US6663880B1 (en) * | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
JP4251988B2 (ja) | 2001-12-14 | 2009-04-08 | ヤーゴテック アクチェンゲゼルシャフト | シクロスポリンを含む医薬製剤およびその使用 |
GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
ES2283756T3 (es) | 2002-03-01 | 2007-11-01 | Novagali Pharma Sa | Sistemas autoemulsionantes de administracion de farmaco para taxoides. |
JP2005527508A (ja) | 2002-03-07 | 2005-09-15 | ヴェクトゥラ リミテッド | 経口デリバリー用急速溶融多粒子製剤 |
EP1485066B1 (fr) | 2002-03-12 | 2016-09-21 | Ethypharm | Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives |
CN1658860A (zh) | 2002-05-03 | 2005-08-24 | 伊丽莎白女王医院研究基金会公司 | 抑制血管生成的方法 |
CN1456350A (zh) | 2002-05-10 | 2003-11-19 | 刘继东 | 环孢素眼用凝胶 |
NZ518997A (en) | 2002-05-16 | 2004-12-24 | Interag | Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent |
US20040057958A1 (en) * | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
US7026374B2 (en) * | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
PT1589031E (pt) | 2002-07-16 | 2007-11-28 | Biotica Tech Ltd | Produção de policétidos e outros produtos naturais |
EP1553940B1 (en) | 2002-07-30 | 2008-02-13 | Wyeth | Parenteral formulations containing a rapamycin hydroxyester |
US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
CA2495103A1 (en) | 2002-08-09 | 2004-02-19 | Sucampo Pharmaceuticals, Inc. | Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases |
US20050031650A1 (en) | 2002-08-26 | 2005-02-10 | Ethypharm | Composition with gelling properties for the sustained delivery of bioactive substances |
CA2498191C (en) | 2002-09-18 | 2012-04-10 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
JP2006507368A (ja) * | 2002-09-29 | 2006-03-02 | サーモディックス,インコーポレイティド | ステロイド含有治療剤の網膜下投与方法;脈絡膜及び網膜に薬力学作用を局在化するための方法;並びに網膜疾患の治療及び/又は予防のための関連する方法 |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
CA2508303C (en) | 2002-12-04 | 2012-10-23 | Santen Pharmaceutical Co., Ltd. | Drug delivery system using subconjunctival depot |
WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
WO2004062669A1 (en) | 2003-01-16 | 2004-07-29 | Sucampo Ag | Use of a macrolide compound for treating dry eye |
EP1599573B1 (en) | 2003-02-17 | 2013-06-19 | Cold Spring Harbor Laboratory | Model for studying the role of genes in tumor resistance to chemotherapy |
US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
WO2004096261A1 (es) | 2003-05-02 | 2004-11-11 | Arturo Jimenez Bayardo | Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante |
US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
SI1635875T1 (sl) | 2003-06-26 | 2009-04-30 | Psivida Inc | Sistem za dajanje zdravila, ki se gelira in situ |
US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
EP1510206A1 (en) | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US20050181018A1 (en) | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
US7402399B2 (en) | 2003-10-14 | 2008-07-22 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
AU2004293071A1 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Polymer compositions and methods for their use |
EP1687041A2 (en) * | 2003-11-20 | 2006-08-09 | Angiotech International AG | Soft tissue implants and anti-scarring agents |
US7186518B2 (en) * | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
US8529939B2 (en) | 2003-12-08 | 2013-09-10 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US20050256081A1 (en) | 2004-02-26 | 2005-11-17 | Peyman Gholam A | Tetracycline derivatives for the treatment of ocular pathologies |
WO2005094279A2 (en) | 2004-03-25 | 2005-10-13 | The Rothberg Institute For Childhood Diseases | Immortalized human tuberous sclerosis null angiomyolipoma cell and method of use thereof |
US7846940B2 (en) | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
DK1755616T3 (da) | 2004-04-08 | 2013-11-25 | Eye Co Pty Ltd | Behandling af ekssudativ retinopati med mineralkortikoider |
US20050232965A1 (en) | 2004-04-15 | 2005-10-20 | Robert Falotico | Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque |
WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20050250804A1 (en) | 2004-05-06 | 2005-11-10 | Glenmark Pharmaceuticals Limited | Pharmaceutical gel formulations |
WO2006002365A2 (en) | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
WO2006002366A2 (en) | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable ocular devices, methods and systems |
US20060018948A1 (en) | 2004-06-24 | 2006-01-26 | Guire Patrick E | Biodegradable implantable medical devices, methods and systems |
AU2005326322B2 (en) * | 2004-07-01 | 2009-02-05 | Yale University | Targeted and high density drug loaded polymeric materials |
US20060110428A1 (en) | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
WO2006020755A2 (en) | 2004-08-10 | 2006-02-23 | Beth Israel Deaconess Medical Center, Inc. | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics |
US20060034891A1 (en) * | 2004-08-12 | 2006-02-16 | Laurie Lawin | Biodegradable controlled release bioactive agent delivery device |
AR050374A1 (es) | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
EP1781672B1 (en) | 2004-08-27 | 2010-10-06 | Cordis Corporation | Solvent free amorphous rapamycin |
AU2005292145C1 (en) | 2004-10-01 | 2011-07-21 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
US20060210604A1 (en) | 2004-10-04 | 2006-09-21 | Eric Dadey | Ocular delivery of polymeric delivery formulations |
US20070299409A1 (en) | 2004-11-09 | 2007-12-27 | Angiotech Biocoatings Corp. | Antimicrobial Needle Coating For Extended Infusion |
DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
US20060257450A1 (en) * | 2005-03-21 | 2006-11-16 | Sreenivasu Mudumba | Drug delivery systems for treatment of diseases or conditions |
CN101137370B (zh) * | 2005-02-09 | 2014-08-13 | 参天制药株式会社 | 用于治疗疾病或病症的液体制剂 |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
WO2006110487A1 (en) | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants for subretinal delivery |
JP2008539276A (ja) | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
US20060247265A1 (en) | 2005-04-28 | 2006-11-02 | Clackson Timothy P | Therapies for treating disorders of the eye |
CN101484575B (zh) | 2005-06-08 | 2013-10-02 | 森托科尔公司 | 用于眼变性的细胞疗法 |
US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
CA2615990A1 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
WO2007047626A1 (en) | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis |
DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
US20070173538A1 (en) | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
KR101411100B1 (ko) | 2006-01-23 | 2014-07-08 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. | 친지성 약물을 함유하는 나노캡슐을 포함하는 미소구체 |
AU2007212271B2 (en) * | 2006-02-09 | 2012-11-01 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
MX2008011013A (es) | 2006-02-28 | 2008-10-23 | Paloma Pharmaceuticals Inc | Composiciones y metodos para tratar enfermedades caracterizadas por proliferacion celular y angiogenesis. |
AU2007230964B2 (en) * | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
-
2006
- 2006-02-09 DK DK06734887.0T patent/DK1848431T3/en active
- 2006-02-09 HU HUE06734887A patent/HUE027352T2/en unknown
- 2006-02-09 CA CA2597596A patent/CA2597596C/en active Active
- 2006-02-09 SI SI200632038A patent/SI1848431T1/sl unknown
- 2006-02-09 US US11/351,844 patent/US20060182771A1/en not_active Abandoned
- 2006-02-09 BR BRPI0608152-5A patent/BRPI0608152A2/pt not_active IP Right Cessation
- 2006-02-09 PL PL06734887T patent/PL1848431T3/pl unknown
- 2006-02-09 KR KR1020077020500A patent/KR20070104931A/ko not_active Application Discontinuation
- 2006-02-09 CA CA002597590A patent/CA2597590A1/en not_active Abandoned
- 2006-02-09 EP EP15198710.4A patent/EP3025713A1/en not_active Withdrawn
- 2006-02-09 US US11/351,761 patent/US20060258698A1/en not_active Abandoned
- 2006-02-09 AU AU2006213588A patent/AU2006213588B2/en active Active
- 2006-02-09 EP EP06734887.0A patent/EP1848431B1/en active Active
- 2006-02-09 KR KR1020147002953A patent/KR101492584B1/ko active IP Right Grant
- 2006-02-09 CN CN201410320617.1A patent/CN104147005B/zh active Active
- 2006-02-09 EP EP06720678A patent/EP1853259A1/en not_active Withdrawn
- 2006-02-09 WO PCT/US2006/004962 patent/WO2006086750A1/en active Application Filing
- 2006-02-09 ES ES06734887.0T patent/ES2564194T3/es active Active
- 2006-02-09 BR BRPI0607606-8A patent/BRPI0607606B1/pt active IP Right Grant
- 2006-02-09 KR KR1020077020502A patent/KR101387456B1/ko active IP Right Grant
- 2006-02-09 GB GB0715745A patent/GB2438544A/en active Pending
- 2006-02-09 JP JP2007555305A patent/JP4974903B2/ja active Active
- 2006-02-09 WO PCT/US2006/004955 patent/WO2006086744A1/en active Application Filing
- 2006-02-09 US US11/352,092 patent/US8637070B2/en not_active Expired - Fee Related
- 2006-02-09 JP JP2007555303A patent/JP2008530127A/ja active Pending
- 2006-02-09 AU AU2006213673A patent/AU2006213673A1/en not_active Abandoned
-
2008
- 2008-04-03 HK HK08103742.7A patent/HK1110215A1/zh unknown
-
2010
- 2010-05-12 US US12/778,872 patent/US8367097B2/en active Active
-
2013
- 2013-01-14 US US13/741,103 patent/US8927005B2/en active Active
-
2014
- 2014-01-09 US US14/151,647 patent/US9387165B2/en active Active
- 2014-11-25 US US14/553,947 patent/US9381153B2/en active Active
-
2015
- 2015-01-30 HK HK15101079.5A patent/HK1200365A1/xx not_active IP Right Cessation
-
2016
- 2016-04-06 CY CY20161100276T patent/CY1117357T1/el unknown
- 2016-06-15 US US15/183,649 patent/US20170020809A1/en not_active Abandoned
- 2016-06-29 US US15/197,568 patent/US20160303093A1/en not_active Abandoned
- 2016-09-05 HK HK16110534.4A patent/HK1222537A1/zh unknown
-
2017
- 2017-06-01 US US15/611,701 patent/US20170266109A1/en not_active Abandoned
- 2017-11-07 US US15/806,226 patent/US20180311152A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7051721B2 (ja) | 2016-06-30 | 2022-04-11 | デュレクト コーポレーション | デポー製剤 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008530127A5 (ja) | ||
JP2008533204A5 (ja) | ||
CA2645488C (en) | Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions | |
KR101492584B1 (ko) | 질환 또는 상태의 치료를 위한 액체 제제 | |
US20170049786A1 (en) | Mtor pathway inhibitors for treating ocular disorders | |
JP2009528276A5 (ja) | ||
US20090324690A1 (en) | Transscleral delivery | |
KR20070121754A (ko) | 질환 또는 상태의 치료를 위한 약물 송달 시스템 | |
KR20100055482A (ko) | 안질환 또는 안이상의 치료를 위한 제제 | |
JP2010536797A5 (ja) | ||
CN101137369A (zh) | 用于眼治疗的制剂 | |
KR20080094814A (ko) | 안정한 제제와 그 제조 및 사용 방법 | |
CN109310680B (zh) | 长效配制物 |